These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19. Dang TTT; Anzurez A; Nakayama-Hosoya K; Miki S; Yamashita K; de Souza M; Matano T; Kawana-Tachikawa A Microbiol Spectr; 2023 Aug; 11(4):e0214323. PubMed ID: 37428088 [TBL] [Abstract][Full Text] [Related]
4. Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8 van den Dijssel J; Hagen RR; de Jongh R; Steenhuis M; Rispens T; Geerdes DM; Mok JY; Kragten AH; Duurland MC; Verstegen NJ; van Ham SM; van Esch WJ; van Gisbergen KP; Hombrink P; Ten Brinke A; van de Sandt CE Clin Transl Immunology; 2022; 11(10):e1423. PubMed ID: 36254196 [TBL] [Abstract][Full Text] [Related]
5. Immunodominant SARS-CoV-2-specific CD4 Ning J; Wang Q; Chen Y; He T; Zhang F; Chen X; Shi L; Zhai A; Li B; Wu C J Med Virol; 2023 Apr; 95(4):e28743. PubMed ID: 37185843 [TBL] [Abstract][Full Text] [Related]
6. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Chen Y; Yin S; Tong X; Tao Y; Ni J; Pan J; Li M; Wan Y; Mao M; Xiong Y; Yan X; Yang Y; Huang R; Wu C; Shen H Clin Microbiol Infect; 2022 Mar; 28(3):410-418. PubMed ID: 34715346 [TBL] [Abstract][Full Text] [Related]
7. CD8 Qiu C; Xiao C; Wang Z; Zhu G; Mao L; Chen X; Gao L; Deng J; Su J; Su H; Fang EF; Zhang ZJ; Zhang J; Xie C; Yuan J; Luo OJ; Huang LA; Wang P; Chen G Front Immunol; 2021; 12():764949. PubMed ID: 35116022 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
11. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
12. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ Front Immunol; 2022; 13():1032911. PubMed ID: 36544780 [TBL] [Abstract][Full Text] [Related]
13. T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients. Li L; Chen Q; Han X; Shen M; Hu C; Chen S; Zhang J; Wang Y; Li T; Huang J; Li S; Hao Y; Jin A Front Cell Dev Biol; 2021; 9():696662. PubMed ID: 34805136 [TBL] [Abstract][Full Text] [Related]
14. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. Zeng Q; Li YZ; Dong SY; Chen ZT; Gao XY; Zhang H; Huang G; Xu Y Front Immunol; 2020; 11():596684. PubMed ID: 33362779 [TBL] [Abstract][Full Text] [Related]
15. Limited Recognition of Highly Conserved Regions of SARS-CoV-2. Swaminathan S; Lineburg KE; Ambalathingal GR; Crooks P; Grant EJ; Mohan SV; Raju J; Panikkar A; Le Texier L; Tong ZWM; Chew KY; Neller MA; Short KR; Gowda H; Gras S; Khanna R; Smith C Microbiol Spectr; 2022 Feb; 10(1):e0278021. PubMed ID: 35196796 [TBL] [Abstract][Full Text] [Related]
16. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Lim HX; Lim J; Jazayeri SD; Poppema S; Poh CL Biomed J; 2021 Mar; 44(1):18-30. PubMed ID: 33727051 [TBL] [Abstract][Full Text] [Related]
17. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
18. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Hellerstein M Vaccine X; 2020 Dec; 6():100076. PubMed ID: 32875286 [TBL] [Abstract][Full Text] [Related]
19. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients. Maghsood F; Shokri MR; Jeddi-Tehrani M; Torabi Rahvar M; Ghaderi A; Salimi V; Kardar GA; Zarnani AH; Amiri MM; Shokri F Pathog Dis; 2022 Feb; 80(1):. PubMed ID: 34994386 [TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2 public CD4+ αβ T cell clonotypes through reverse epitope discovery. Rosati E; Pogorelyy MV; Minervina AA; Scheffold A; Franke A; Bacher P; Thomas PG bioRxiv; 2021 Nov; ():. PubMed ID: 34845450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]